Diagnosis and selection of alternative antibiotics in beta-lactams hypersensitivity reactions: Current recommendations and challenges
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110573 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Zahra Kanannejad und 6 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Drug Hypersensitivity, Anaphylaxis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 107 Literaturangaben.
Abstract (Originalsprache)
Beta-lactam (BLM) antibiotics, including amino-penicillin and cephalosporins, are typically the first-choice treatment for bacterial infections. However, adverse reactions to these antibiotics are frequently reported, causing non-allergist physicians to select alternative broad-spectrum antibiotics that can have harmful consequences. Patients with unclear histories of hypersensitivity reactions to BLMs should undergo an allergy workup to establish a firm diagnosis, particularly when different drugs are prescribed simultaneously. However, finding the safest, most precise, and cost-effective methods for confirming BLMs hypersensitivity and selecting the most appropriate alternative BLM is uncertain, particularly in severe delayed reactions. This review aims to provide data and recommendations on the availability and validity of skin tests (STs), drug provocation test (DPT) protocols, based on the latest published literature and guideline. To make the process more practical, we focused on cross-reactivity between BLMs and diagnostic tests. There are two main novel aspects of this document: 1) For T-cell-mediated reactions, patient stratification into high, moderate, and low-risk groups based on the mortality and morbidity of adverse drug reactions. 2) For IgE-mediated reactions, stratification of individuals with isolated limited urticarial without anaphylaxis in a low-risk group and removal of the extensive limitation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
- Department of Pediatrics, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
- Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Allergy and Clinical Immunology, Namazi Hospital, Shiraz, Iran. Electronic address: a_pourvali@yahoo.com.
- Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran; Children's Medical Center, Pediatric Center of Excellence, Tehran University of Medical, Sciences, Tehran, Iran.
- Department of Allergy and Clinical Immunology, Rasoole- Akaram Medical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Science, Tehran, Iran.
- Allergist and Clinical Immunologist, Clinical Research Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Iran.
Zitieren
APA
Kanannejad, Z., Pourvali, A., Esmaeilzadeh, H., Shokouhi Shoormasti, R., Reza Fazlollahi, M., Fallahpour, M., & Zaremehrjardi, F. (2023). Diagnosis and selection of alternative antibiotics in beta-lactams hypersensitivity reactions: Current recommendations and challenges. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110573
Vancouver
Kanannejad Z, Pourvali A, Esmaeilzadeh H, Shokouhi Shoormasti R, Reza Fazlollahi M, Fallahpour M, et al. Diagnosis and selection of alternative antibiotics in beta-lactams hypersensitivity reactions: Current recommendations and challenges. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110573
BibTeX
@article{Kanannejad2023,
author = {Kanannejad, Zahra and Pourvali, Ali and Esmaeilzadeh, Hossein and Shokouhi Shoormasti, Raheleh and Reza Fazlollahi, Mohammad and Fallahpour, Morteza and Zaremehrjardi, Fatemeh},
title = {Diagnosis and selection of alternative antibiotics in beta-lactams hypersensitivity reactions: Current recommendations and challenges},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110573}
}
EUVIMED